Shares of Inari Medical NARI moved higher in after-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share were up 44.44% over the past year to $0.13, which beat the estimate of $0.05.
Revenue of $57,397,000 higher by 18.10% year over year, which beat the estimate of $55,130,000.
Guidance
Earnings guidance hasn't been issued by the company for now.
The upcoming fiscal year's revenue expected to be between $240,000,000 and $250,000,000.
How To Listen To The Conference Call
Date: May 11, 2021
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/kc8jykxe
Price Action
Company's 52-week high was at $127.42
Company's 52-week low was at $39.55
Price action over last quarter: down 19.85%
Company Overview
Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from venous diseases. Its product portfolio includes ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTreiver product is used for the treatment of pulmonary embolism. Geographically, the company has its presence across the United States.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
